Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inflammatory mediators and dual depression, Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders

  • García Marchena, Nuria|||0000-0002-0575-3613
  • Barrera-Conde, Marta|||0000-0002-0106-0000
  • Mestre-Pintó, Joan-Ignasi|||0000-0003-0387-9375
  • Araos, Pedro|||0000-0001-5172-8796
  • Serrano, Antonia
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Papaseit, Esther|||0000-0003-2620-4274
  • Fonseca, Francina|||0000-0002-0779-6545
  • Ruiz, Juan Jesús
  • Rodríguez de Fonseca, Fernando|||0000-0002-4516-5795
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Pavón, Francisco Javier
  • Torrens, Marta
Major depressive disorder (MDD) is the most prevalent comorbid mental disorder among people with substance use disorders. The MDD can be both primary and substance-induced and its accurate diagnosis represents a challenge for clinical practice and treatment response. Recent studies reported alterations in the circulating expression of inflammatory mediators in patients with psychiatric disorders, including those related to substance use. The aim of the study was to explore TNF-α, IL-1β, CXCL12, CCL2, CCL11 (eotaxin-1) and CX3CL1 (fractalkine) as potential biomarkers to identify comorbid MDD and to distinguish primary MDD from substance-induced MDD in patients with substance disorders. Patients diagnosed with cocaine (CUD, n = 64) or alcohol (AUD, n = 65) use disorders with/without MDD were recruited from outpatient treatment programs [CUD/non-MDD (n = 31 CUD/primary MDD (n = 18 CUD/cocaine-induced MDD (N = 15 AUD/non-MDD (n = 27 AUD/primary MDD (n = 16) and AUD/alcohol-induced MDD (n = 22)]. Sixty-two healthy subjects were also recruited as control group. Substance and mental disorders were assessed according to "Diagnostic and Statistical Manual of Mental Disorders, 4 edition, text revision" (DSM-IV-TR) and a blood sample was collected for determinations in the plasma. The cocaine group showed lower TNF-α (p<0.05) and CCL11 (p<0.05), and higher IL-1β (p<0.01) concentrations than the control group. In contrast, the alcohol group showed higher IL-1β (p<0.01) and lower CXCL12 (p<0.01) concentrations than the control group. Regarding MDD, we only observed alterations in the cocaine group. Thus, CUD/MDD patients showed lower IL-1β (p<0.05), CXCL12 (p<0.05) and CCL11 (p<0.05), and higher CXC3CL1 (p<0.05) concentrations than CUD/non-MDD patients. Moreover, while CUD/primary MDD patients showed higher CCL11 (p<0.01) concentrations than both CUD/non-MDD and CUD/cocaine-induced MDD patients, CUD/cocaine-induced MDD patients showed lower CXCL12 (p<0.05) concentrations than CUD/non-MDD patients. Finally, a logistic regression model in the cocaine group identified CXCL12, CCL11 and sex to distinguish primary MDD from cocaine-induced MDD providing a high discriminatory power. The present data suggest an association between changes in inflammatory mediators and the diagnosis of primary and substance-induced MDD, namely in CUD patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Therapeutic Use of LSD in Psychiatry, A Systematic Review of Randomized-Controlled Clinical Trials

  • Fuentes, Juan José
  • Fonseca, Francina|||0000-0002-0779-6545
  • Elices, M.|||0000-0002-7034-4242
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Torrens, Marta
Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a resurgence of interest in LSD research and its therapeutic potential for psychiatry. The aim of this review is to identify controlled and randomized clinical trials that assess the potential use of LSD in psychiatry. PRISMA guidelines for systematic review were followed. A literature search of PubMed and Psychedelic bibliography from Multidisciplinary Association for Psychedelic Studies (MAPS) databases was performed as well as a manual search of references from evaluated studies. Only randomized-controlled clinical trials were included. Study quality was systematically calculated by using the Cochrane Collaboration Tool for assessing risk of bias. A final selection of 11 articles was made after considering inclusion and exclusion criteria. LSD was administered to 567 patients in a dose ranging from 20 to 800 mcg. Despite the design heterogeneity of clinical trials, positive results were observed, thus revealing the therapeutic potential of LSD to reduce psychiatric symptomatology, mainly in alcoholism. The vast majority of authors describe significant and positive short-term changes in patients, despite the fact that in some studies an important homogenization was observed between the LSD treatment group and control group at long-term follow-up. Multiple variables regarding LSD treatment therapeutic approach and quality of experience were revealed and related to therapeutic outcomes. LSD is revealed as a potential therapeutic agent in psychiatry; the evidence to date is strongest for the use of LSD in the treatment of alcoholism. Despite the difficulty of designing proper double blind clinical trials with this substance, new studies that conform to modern standards are necessary in order to strengthen our knowledge on its use and open new doors in the future.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cannabinoids, from pot to lab

  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Pérez-Acevedo, Ana Pilar|||0000-0001-5647-4529
  • Hladun, Olga|||0000-0002-6230-5876
  • Torres-Moreno, M. Carmen
  • Muga, Roberto|||0000-0001-6301-431X
  • Torrens, Marta|||0000-0001-6222-4761
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
Cannabis is becoming increasingly present in our society. In recent years, the line between the natural (cannabis) and the synthetic (synthetic cannabinoids), the recreational (cannabis) and the medical (pharmaceutical cannabinoids and medical cannabis) has been crossed. In this paper we review some of the novel aspects of cannabis and cannabinoids in relation to their legal situation, changes in their composition and forms of cannabis use, the concept of medical cannabis, and synthetic cannabinoids as new psychoactive substances (NPS). We have also analyzed serious adverse reactions and intoxications associated with the use of synthetic cannabinoids, as well as the latest developments in the research of pharmaceutical cannabinoids.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations, A Systematic Review

  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Pérez-Acevedo, Ana Pilar|||0000-0001-5647-4529
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Martín, Soraya|||0009-0008-3761-9217
  • Hladun, Olga|||0000-0002-6230-5876
  • Siles, Adrià
  • Torrens, Marta
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
Background and objective : Changes in cannabis legalization regimes in several countries have influenced the diversification of cannabis use. There is an ever-increasing number of cannabis forms available, which are gaining popularity for both recreational and therapeutic use. From a therapeutic perspective, oral cannabis containing Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is a promising route of administration but there is still little information about its pharmacokinetics (PK) effects in humans. The purpose of this systematic review is to provide a general overview of the available PK data on cannabis and THC after oral administration. Materials and Methods : A search of the published literature was conducted using the PubMed database to collect available articles describing the PK data of THC after oral administration in humans. Results : The literature search yielded 363 results, 26 of which met our inclusion criteria. The PK of oral THC has been studied using capsules (including oil content), tablets, baked goods (brownies and cookies), and oil and tea (decoctions). Capsules and tablets, which mainly correspond to pharmaceutical forms, were found to be the oral formulations most commonly studied. Overall, the results reflect the high variability in the THC absorption of oral formulations, with delayed peak plasma concentrations compared to other routes of administration. Conclusions : Oral THC has a highly variable PK profile that differs between formulations, with seemingly higher variability in baked goods and oil forms. Overall, there is limited information available in this field. Therefore, further investigations are required to unravel the unpredictability of oral THC administration to increase the effectiveness and safety of oral formulations in medicinal use.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis

  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Pérez-Acevedo, Ana Pilar|||0000-0001-5647-4529
  • Pacifici, Roberta
  • Mannocchi, Giulio
  • Gottardi, Massimo
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Martín, Soraya|||0009-0008-3761-9217
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Pichini, Simona
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
Inhalation by vaporization is a useful application mode for medical cannabis. In this study, we present the disposition of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, and their metabolites in serum, oral fluid, and urine together with the acute pharmacological effects in 14 healthy individuals treated with vaporized medical cannabis. THC and CBD peaked firstly in serum and then in oral fluid, with higher concentrations in the first biological matrices and consequent higher area under the curve AUCs. Acidic precursors Δ-9-tetrahydrocannabinolic acid A (THCA) and cannabidiolic acid (CBDA) showed a similar time course profile but lower concentrations due to the fact that vaporization partly decarboxylated these compounds. All THC and CBD metabolites showed a later onset with respect to the parent compounds in the absorption phase and a slower decrease to baseline. In agreement with serum kinetics, THC-COOH-GLUC and 7-COOH-CBD were the significantly most excreted THC and CBD metabolites. The administration of vaporized medical cannabis induced prototypical effects associated with the administration of cannabis or THC in humans, with a kinetic trend overlapping that of parent compounds and metabolites in serum. The pharmacokinetics of cannabinoids, their precursors, and their metabolites in biological fluids of individuals treated with vaporized medical cannabis preparations showed a high interindividual variability as in the case of oral medical cannabis decoction and oil. Inhaled medical cannabis was absorbed into the organism earlier than decoction and oil. Cannabinoids reached higher systemic concentrations, also due to the fact that the acid precursors decarboxylated to parent cannabinoids at high temperatures, and consequently, the physiological and subjective effects occurred earlier and resulted with higher intensity. No serious adverse effects were observed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Acute Pharmacological Effects of Oral and Intranasal Mephedrone, an observational study in humans

  • Papaseit, Esther|||0000-0003-2620-4274
  • Olesti, Eulàlia|||0000-0001-8677-9964
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Torrens, Marta
  • Fonseca, Francina|||0000-0002-0779-6545
  • Grifell, Marc|||0000-0001-9815-5761
  • Ventura, Mireia|||0000-0003-1133-6872
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
Mephedrone (4-methylmethcathinone) is a synthetic cathinone with psychostimulant properties which remains one of the most popular new psychoactive substances (NPS). It is frequently used orally and/or intranasally. To date, no studies have evaluated the acute effects and pharmacokinetics after self-administration of mephedrone orally (ingestion) and intranasally (insufflation) in naturalistic conditions. An observational study was conducted to assess and compare the acute pharmacological effects, as well as the oral fluid (saliva) concentrations of mephedrone self-administered orally and intranasally. Ten healthy experienced drug users (4 females and 6 males) self-administered a single dose of mephedrone, orally (n = 5, 100-200 mg; mean 150 mg) or intranasally (n = 5, 50-100 mg, mean 70 mg). Vital signs (blood pressure, heart rate, and cutaneous temperature) were measured at baseline (0), 1, 2, and 4 h after self-administration. Each participant completed subjective effects questionnaires: A set of Visual Analogue Scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI), and Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) at baseline, 1, 2, and 4 h after self-administration. Oral fluid and urine were collected during 4 h. Both routes of mephedrone self-administration enhanced ratings of euphoria and well-being effects and increased cardiovascular effects in humans. Although it was at times assessed that the oral route produced greater and larger effects than the intranasal one, concentrations of mephedrone in oral fluid and also the total amount of mephedrone and metabolites in urine showed of mephedrone are considerably higher when self-administered intranasally in comparison to orally. Controlled clinical trials are needed to confirm our observational results.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Long-Term Outcomes of Patients With Cocaine Use Disorder, A 18-years Addiction Cohort Study

  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Zuluaga Cruz, Andrea Paola|||0000-0002-3003-4856
  • Fuster, Daniel|||0000-0003-1262-5860
  • Papaseit, Esther|||0000-0003-2620-4274
  • Galan, Sara
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Muga, Roberto|||0000-0001-6301-431X
Objective: Cocaine Use Disorder (CUD) has been associated with multiple complications and premature death. The purpose of the present study was to analyze the relationship between baseline medical comorbidity and long-term medical outcomes (i.e., hospitalization, death) in a cohort of patients primarily admitted for detoxification. In addition, we aimed to analyze cause-specific mortality. Methods: longitudinal study in CUD patients admitted for detoxification between 2001 and 2018. Substance use characteristics, laboratory parameters and medical comorbidity by VACS Index were assessed at admission. Follow-up and health-related outcomes were ascertained through visits and e-health records. Kaplan-Meier and Cox regression models were used to analyze survival and predictors of hospitalization and death. Results: 175 patients (77.7% men) were included. Age at admission was 35 years [IQR: 30-41 years], 59.4% of the patients being intranasal users, 33.5% injectors, and 7.1% smokers. Almost 23% of patients had concomitant alcohol use disorder, 39% were cannabis users and 9% opiate users. The median VACS Index score on admission was 10 points [IQR: 0-22]. After 12 years [IQR: 8.6-15 years] of follow-up there were 1,292 (80.7%) ED admissions and 308 (19.3%) hospitalizations. The incidence rate of ED admission and hospitalization was 18.6 × 100 p-y (95% CI: 15.8-21.8 × 100 p-y). Mortality rate was 1.4 × 100 p-y (95% CI: 0.9-2.0 × 100 p-y) and, baseline comorbidity predicted hospitalization and mortality: those with VACS Index.
Dipòsit Digital de Documents de la UAB
Publication

Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program, A longitudinal study

  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Rivas, Inmaculada|||0000-0003-2633-5530
  • Faure, Eva|||0000-0002-5056-0888
  • Espinach, Néstor|||0000-0002-5726-5435
  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Majó, Xavier|||0000-0003-4338-6014
  • Colom Farran, J.|||0000-0001-6861-7865
  • Muga, Roberto|||0000-0001-6301-431X
Direct-acting antivirals (DAAs) are recommended for the treatment of hepatitis C virus (HCV) infection in patients treated with methadone or buprenorphine. To assess HCV treatment rates in an Opioid Treatment Program (OTP). This longitudinal study included 501 patients (81.4% men, median age: 45 years; interquartile range: 39-50 years) enrolled in an OTP between October 2015 and September 2017. Patients were followed until September 2019. Data on socio-demographics, substance use, HCV infection, human immunodeficiency virus (HIV) infection and laboratory parameters were collected at entry. We analyzed medical records to evaluate HCV treatment. Kaplan-Meier methods and Cox regression models were used to analyze the DAA treatment uptake and to identify treatment predictors. Prevalence of HCV and HIV infection was 70% and 34%, respectively. Among anti-HCV-positive (n = 336) patients, 47.2%, 41.3%, and 31.9% used alcohol, cannabis, and cocaine, respectively. HCV-RNA tests were positive in 233 (69.3%) patients. Twentyeight patients (8.3%) cleared the infection, and 59/308 (19.1%) had received interferon-based treatment regimens before 2015. Among 249 patients eligible, 111 (44.6%) received DAAs. Treatment rates significantly increased over time from 7.8/100 person-years (p-y) (95%CI: 5.0-12.3) in 2015 to 18.9/100 p-y (95%CI: 11.7-30.3) in 2019. In a multivariate analysis, patients with HIV co-infection were twice as likely to receive DAAs (HR = 1.94, 95%CI: 1.21-3.12) than patients with HCV mono-infection. Current drug use was an independent risk factor for not receiving treatment against infection (HR = 0.48, 95%CI: 0.29-0.80). HCV treatment is evolving in patients with HCV-HIV co-infection. Ongoing drug use while in an OTP might negatively impact the readiness to treat infection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Acute Pharmacological Effects and Oral Fluid Biomarkers of the Synthetic Cannabinoid UR-144 and THC in Recreational Users

  • La Maida, Nunzia|||0000-0003-0127-4225
  • Papaseit, Esther|||0000-0003-2620-4274
  • Martínez, Lucia|||0000-0002-2941-0922
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Pellegrini, Manuela|||0000-0003-3348-5297
  • Pichini, Simona
  • Pacifici, Roberta
  • Ventura, Mireia|||0000-0003-1133-6872
  • Galindo, Liliana|||0000-0002-2396-4772
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
UR-144 is a synthetic cannabinoid found in herbal incenses for recreational use as a substitute of cannabis. It is a cannabinoid receptor agonist with effects on the central nervous system similar to those of THC. Several cases of intoxication involving UR-144 consumption have been reported. An observational study was carried out to assess UR-144 acute pharmacological effects in comparison with cannabis measuring biomarkers of disposition in oral fluid. Both UR-144 and THC increased blood pressure and heart rate. THC induced stimulant-like and high effects significantly more than those of UR-144 and the two parent drugs could be measured in oral fluid as biomarkers of consumption within 3 h following smoking of the substance. Synthetic cannabinoids (SCs) are one of the most frequent classes of new psychoactive substances monitored by the EU Early Warning System and World Health Organization. UR-144 is a SC with a relative low affinity for the CB1 receptor with respect to that for the CB2 receptor. As with other cannabinoid receptor agonists, it has been monitored by the EU Early Warning System since 2012 for severe adverse effects on consumers. Since data for UR-144 human pharmacology are very limited, an observational study was carried out to evaluate its acute pharmacological effects following its administration using a cannabis joint as term of comparison. Disposition of UR-144 and delta-9-tetrahydrocannibinol (THC) was investigated in oral fluid. Sixteen volunteers smoked a joint prepared with tobacco and 1 or 1.5 mg dose of UR-144 (n = 8) or cannabis flowering tops containing 10 or 20 mg THC (n = 8). Physiological variables including systolic and diastolic blood pressure, heart rate and cutaneous temperature were measured. A set of Visual Analog Scales (VAS), the Addiction Research Centre Inventory (ARCI)-49-item short form version and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) were administered to evaluate subjective effects. Oral fluid was collected at baseline, 10, 20, 40 min and 1, 2, 3 and 4 h after smoking, for UR-144 or THC concentration monitoring. Results showed significant statistical increases in both systolic and diastolic blood pressure and heart rate after both UR-144 and cannabis smoking. Both substances produced an increase in VAS related to stimulant-like and high effects, but scores were significantly higher after cannabis administration. No hallucinogenic effects were observed. Maximal oral fluid UR-144 and THC concentrations appeared at 20 and 10 min after smoking, respectively. The presence of UR-144 in oral fluid constitutes a non-invasive biomarker of SC consumption. The results of this observational study provide valuable preliminary data of the pharmacological effects of UR-144, showing a similar profile of cardiovascular effects in comparison with THC but lower intensity of subjective effects. Our results have to be confirmed by research in a larger sample to extensively clarify pharmacological effects and the health risk profile of UR-144.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use

  • Fuster, Daniel|||0000-0003-1262-5860
  • García Calvo, Xavier|||0000-0001-8165-8717
  • Zuluaga Blanco, Yenny Paola|||0000-0002-0247-0351
  • Bolao, Ferran|||0000-0002-9104-6615
  • Muga, Roberto|||0000-0001-6301-431X
Hepatitis C virus (HCV) infection and unhealthy alcohol use are major drivers of the burden of liver disease worldwide and commonly co-occur. Assessment of underlying liver damage is a cornerstone of the clinical care of patients with chronic HCV infection and/or unhealthy alcohol use because many of them are diagnosed at advanced stages of disease. Early diagnosis of liver disease before decompensated liver cirrhosis becomes established is essential for treatment with direct acting antivirals and/or abstinence from alcohol consumption, which are the main therapeutic approaches for clinical management. In this review, we discuss current knowledge around the use of non-invasive methods to assess liver disease, such as abdominal ultrasound, controlled attenuation parameter, transient elastography, magnetic resonance imaging, and indices based on serum markers of liver injury.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Determination of the Synthetic Cannabinoids JWH-122, JWH-210, UR-144 in Oral Fluid of Consumers by GC-MS and Quantification of Parent Compounds and Metabolites by UHPLC-MS/MS

  • La Maida, Nunzia|||0000-0003-0127-4225
  • Pellegrini, Manuela|||0000-0003-3348-5297
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Ventura, Mireia|||0000-0003-1133-6872
  • Galindo, Liliana|||0000-0002-2396-4772
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Pichini, Simona
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Marchei, Emilia|||0000-0002-7158-6032
The consumption of synthetic cannabinoids (SCs) has significantly increased in the last decade and the analysis of SCs and their metabolites in human specimens is gaining interest in clinical and forensic toxicology. A pilot study has been carried out using a combination of an initial last generation gas chromatography-mass spectrometry (GC-MS) screening method for the determination of JWH-122, JWH-210, UR-144) in oral fluid (OF) of consumers and an ultra-high performance liquid chromatography high resolution mass spectrometry (UHPLC-HRMS) confirmatory method for the quantification of the parent compounds and their metabolites in the same biological matrix. OF samples were simply liquid-liquid extracted before injecting in both chromatographic systems. The developed methods have been successfully validated and were linear from limit of quantification (LOQ) to 50 ng/mL OF. Recovery of analytes was always higher than 70% and matrix effect always lower than 15% whereas intra-assay and inter-assay precision and accuracy were always better than 16%. After smoking 1 mg JWH-122 or UR-144 and 3 mg JWH-210, maximum concentration of 4.00-3.14 ng/mL JWH-122, 8.10-7.30 ng/mL JWH-210 ng/mL and 7.40 and 6.81 ng/mL UR-144 were measured by GC-MS and UHPLC-HRMS respectively at 20 min after inhalation. Metabolites of JWH 122 and 210 were quantified in OF by UHPLC-HRMS, while that of UR144 was only detectable in traces. Our results provide for the first time information about disposition of these SCs and their metabolites in consumers OF. Last generation GC-MS has proven useful tool to identify and quantify parent SCs whereas UHPLC-HRMS also confirmed the presence of SCs metabolites in the OF of SCs consumers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Acute Pharmacological Effects of 2C-B in Humans, An Observational Study

  • Papaseit, Esther|||0000-0003-2620-4274
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Torrens, Marta
  • Ventura, Mireia|||0000-0003-1133-6872
  • Pujadas, Mitona|||0000-0002-0506-3030
  • Torre, Rafael de la|||0000-0002-6765-1866
  • González, Débora|||0000-0002-5353-4351
2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenylethylamine derivative, structurally similar to mescaline. It is a serotonin 5-hydroxytryptamine-2A (5-HT), 5-hydroxytryptamine-2B (5-HT), and 5-hydroxytryptamine-2C (5-HT) receptor partial agonist used recreationally as a new psychoactive substance. It has been reported that 2C-B induces mild psychedelic effects, although its acute pharmacological effects and pharmacokinetics have not yet been fully studied in humans. An observational study was conducted to assess the acute subjective and physiological effects, as well as pharmacokinetics of 2C-B. Sixteen healthy, experienced drug users self-administered an oral dose of 2C-B (10, 15, or 20 mg). Vital signs (blood pressure and heart rate) were measured at baseline 1, 2, 3, 4, and 6 hours (h). Each participant completed subjective effects using three rating scales: the visual analog scale (VAS), the Addiction Research Centre Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) at baseline, 2-3 and 6 h after self-administration (maximum effects along 6 h), and the Hallucinogenic Rating Scale (maximum effects along 6 h). Oral fluid (saliva) was collected to assess 2C-B and cortisol concentrations during 24 h. Acute administration of 2C-B increased blood pressure and heart rate. Scores of scales related to euphoria increased (high, liking, and stimulated), and changes in perceptions (distances, colors, shapes, and lights) and different body feelings/surrounding were produced. Mild hallucinating effects were described in five subjects. Maximum concentrations of 2C-B and cortisol were reached at 1 and 3 h after self-administration, respectively. Oral 2C-B at recreational doses induces a constellation of psychedelic/psychostimulant-like effects similar to those associated with serotonin-acting drugs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Alcohol Consumption and Hepatitis C Virus (HCV) RNA Levels in HIV/HCV Coinfected Patients

  • Fuster, Daniel|||0000-0003-1262-5860
  • Nunes, David
  • Cheng, Debbie
  • Saitz, Richard
  • Samet, Jeffrey H.|||0000-0002-0897-3400
Background: The impact of Hepatitis C virus (HCV) RNA levels on the evolution of chronic HCV infection-related liver damage is controversial. Heavy alcohol use is believed to have a deleterious impact on the course of HCV disease, but current knowledge about the possible effect of alcohol use on HCV RNA levels in HIV/HCV coinfected patients is limited. Methods: We examined 107 HIV/HCV-infected individuals with current or past unhealthy alcohol use to assess the association between alcohol consumption (any drinking vs. abstinent) and HCV RNA levels. Results: Participants were 75% male, with a mean age of 43 years, and 63% were on antiretroviral therapy. Mean (SD) log HIV RNA was 3.1 (1.4) and mean (SD) log HCV RNA was 6.1 (0.8). Past-month alcohol use was present in 38% of participants. In a multivariable linear regression analysis we found no significant differences in mean log HCV RNA levels between those reporting alcohol use and those who were abstinent [β (95%CI): -0.04 (-0.34, 0.26), p = 0.79)]. There was no significant association between any heavy drinking day and HCV RNA level (0.07, 95% CI: (-0.24, 0.38), p = 0.66). Conclusions: We did not detect significant associations between alcohol use and HCV RNA levels among HIV/HCV coinfected patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry and High-Sensitivity Gas Chromatography-Mass Spectrometry Screening of Classic Drugs and New Psychoactive Substances and Metabolites in Urine of Consumers

  • Marchei, Emilia|||0000-0002-7158-6032
  • Alías Ferri, María|||0000-0002-2237-8392
  • Torrens, Marta
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Pacifici, Roberta
  • Pichini, Simona
  • Pellegrini, Manuela|||0000-0003-3348-5297
The use of the new psychoactive substances is continuously growing and the implementation of accurate and sensible analysis in biological matrices of users is relevant and fundamental for clinical and forensic purposes. Two different analytical technologies, high-sensitivity gas chromatography-mass spectrometry (GC-MS) and ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS) were used for a screening analysis of classic drugs and new psychoactive substances and their metabolites in urine of formed heroin addicts under methadone maintenance therapy. Sample preparation involved a liquid-liquid extraction. The UHPLC-HRMS method included Accucore™ phenyl Hexyl (100 × 2.1 mm, 2.6 μm, Thermo, USA) column with a gradient mobile phase consisting of mobile phase A (ammonium formate 2 mM in water, 0.1% formic acid) and mobile phase B (ammonium formate 2 mM in methanol/acetonitrile 50:50 (v / v), 0.1% formic acid) and a full-scan data-dependent MS2 (ddMS2) mode for substances identification (mass range 100-1000 m / z). The GC-MS method employed an ultra-Inert Intuvo GC column (HP-5MS UI, 30 m, 250 µm i.d, film thickness 0.25 µm; Agilent Technologies, Santa Clara, CA, USA) and electron-impact (EI) mass spectra were recorded in total ion monitoring mode (scan range 40-550 m / z). Urine samples from 296 patients with a history of opioid use disorder were examined. Around 80 different psychoactive substances and/or metabolites were identified, being methadone and metabolites the most prevalent ones. The possibility to screen for a huge number of psychotropic substances can be useful in suspected drug related fatalities or acute intoxication/exposure occurring in emergency departments and drug addiction services.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prevalence and associations of metabolic syndrome in patients with alcohol use disorder

  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Bolao, Ferran|||0000-0002-9104-6615
  • Cachón-Suárez, Isabel
  • Garcia-Martín, Carme
  • Short, Antoni
  • Bataller, Ramon|||0000-0002-1119-7799
  • Muga, Roberto|||0000-0001-6301-431X
Excessive alcohol consumption has been associated with different components of the metabolic syndrome (MetS) such as arterial hypertension, dyslipidemia, type 2 diabetes or obesity. We aimed to analyze the prevalence and associations of MetS in patients with Alcohol Use Disorder (AUD). Cross-sectional study in heavy drinkers admitted for the treatment of AUD between 2013 and 2017. Medical comorbidity, anthropometric data, alcohol use and biological parameters were obtained. MetS was established according to the harmonized definition. A total of 728 patients (22% women) were included; median age was 47 years (IQR: 40-53.5), median alcohol consumption was 160 g/day (IQR: 115-240) and prevalence of MetS was 13.9%. The multivariate analysis showed a significant dose-response effect of estimated glomerular filtration (eGFR) and MetS: relative to patients with eGFR.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression

  • Fonseca, Francina|||0000-0002-0779-6545
  • Mestre-Pintó, Joan-Ignasi|||0000-0003-0387-9375
  • Rodríguez-Minguela, Rocío
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Langohr, Klaus|||0000-0001-7075-9192
  • Barbuti, Margherita
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Torrens, Marta
Major depressive disorder (MDD) and cocaine use disorder (CUD) are related with disability and high mortality rates. The assessment and treatment of psychiatric comorbidity is challenging due to its high prevalence and its clinical severity, mostly due to suicide rates and the presence of medical comorbidities. The aim of this study is to investigate differences in brain derived neurotrophic factor (BDNF) and cortisol plasmatic levels in patients diagnosed with CUD-primary-MDD and CUD-induced-MDD and also to compare them to a sample of MDD patients (without cocaine use), a sample of CUD (without MDD), and a group of healthy controls (HC) after a stress challenge. A total of 46 subjects were included: MDD (n = 6), CUD (n = 15), CUD-primary-MDD (n = 16), CUD-induced-MDD (n = 9), and 21 HC. Psychiatric comorbidity was assessed with the Spanish version of the Psychiatric Research Interview for Substance and Mental Disorders IV (PRISM-IV), and depression severity was measured with the Hamilton Depression Rating Scale (HDRS). Patients were administered the Trier Social Stress Test (TSST) before and after the biological measures, including BDNF, and cortisol levels were obtained. After the TSST, Cohen's d values between CUD-primary-MDD and CUD-induced-MDD increased in each assessment from 0.19 post-TSST to 2.04 post-90-TSST. Pairwise differences among CUD-induced-MDD and both MDD and HC groups had also a large effect size value in post-30-TSST and post-90-TSST. In the case of the BDNF concentrations, CUD-primary-MDD and CUD-induced-MDD in post-90-TSST (12,627.27 ± 5488.09 vs.17,144.84 ± 6581.06, respectively) had a large effect size (0.77). Results suggest a different pathogenesis for CUD-induced-MDD with higher levels of cortisol and BDNF compared with CUD-primary-MDD. Such variations should imply different approaches in treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CANreduce-SP-adding psychological support to web-based adherence-focused guided self-help for cannabis users, study protocol for a three-arm randomized control trial

  • Mestre-Pintó, Joan-Ignasi|||0000-0003-0387-9375
  • Fonseca, Francina|||0000-0002-0779-6545
  • Schaub, Michael P.
  • Baumgartner, Christian
  • Alías Ferri, María|||0000-0002-2237-8392
  • Torrens, Marta|||0000-0001-6222-4761
Cannabis is the most-frequently used illicit drug in Europe. Over the last few years in Spain, treatment demand has increased, yet most cannabis users do not seek treatment despite the related problems. A web-based self-help tool, like CANreduce 2.0, could help these users to control their consumption. This study protocol describes a three-arm randomized controlled trial (RCT) comparing the effectiveness of three approaches, in terms of reducing cannabis use among problematic cannabis users, the first two treatment arms including the Spanish version of CANreduce 2.0 (an adherence-focused, guidance-enhanced, web-based self-help tool) (1) with and (2) without psychological support; and the third group (3) treatment as usual (TAU). Study hypotheses will be tested concerning the primary outcome: change in the number of days of cannabis use over the previous week, comparing assessments at 6 weeks and 3 and 6 months follow-up between groups and against baseline. Secondary outcomes related to cannabis use will be tested similarly. Mental disorders will be explored as predictors of adherence and outcomes. Analyses will be performed on an intention-to-treat basis, then verified by complete case analyses. This study will test how effective the Spanish version of CANreduce 2.0 (CANreduce-SP) is at reducing both the frequency and quantity of cannabis use in problematic users and whether adding psychological support increases its effectiveness. This trial is registered with the Clinical Trials Protocol Registration and Results System (PRS) number: . Registered 18 August 2020, (Archived by archive.is ). The project commenced in November 2020 and recruitment is anticipated to end by November 2022.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Interaction of Energy Drinks with Prescription Medication and Drugs of Abuse

  • Hladun, Olga|||0000-0002-6230-5876
  • Papaseit, Esther|||0000-0003-2620-4274
  • Martín, Soraya|||0009-0008-3761-9217
  • Barriocanal, Ana María|||0000-0002-4159-519X
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
In recent years, the consumption of energy drinks (EDs) has become increasingly popular, especially among adolescents. Caffeine, a psychostimulant, is the main compound of EDs which also contain other substances with pharmacological effects. This review aims to compile current evidence concerning the potential interactions between EDs, medicines, and drugs of abuse as they are frequently consumed in combination. The substances involved are mainly substrates, inductors or inhibitors of CYP1A2, psychostimulants, alcohol and other depressant drugs. Furthermore, intoxications reported with EDs and other substances have also been screened to describe acute toxicity. The results of our review show that the consumption of both EDs alone and in combination is not as safe as previously thought. Health professionals and consumers need to be aware of the potential interactions of these drinks as well as the absence of long-term safety data.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Acute Pharmacological Effects and Oral Fluid Concentrations of the Synthetic Cannabinoids JWH-122 and JWH-210 in Humans After Self-Administration, An Observational Study

  • Martínez, Lucia|||0000-0002-2941-0922
  • La Maida, Nunzia|||0000-0003-0127-4225
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Pellegrini, Manuela|||0000-0003-3348-5297
  • Pichini, Simona
  • Ventura, Mireia|||0000-0003-1133-6872
  • Galindo, Liliana|||0000-0002-2396-4772
  • Busardo, Francesco Paolo|||0000-0002-3082-4532
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
Synthetic cannabinoids (SCs) are a group of new psychoactive drugs used recreationally with potential health risks. They are monitored by the EU Early Warning System since 2010 due to severe adverse effects on consumers. JWH-122 and JWH-210 are naphthoylindole SCs and potent cannabinoid receptor CB1 and CB2 agonists. Information about the effects of SCs usually is available from intoxication cases and surveys, and few studies on humans after controlled administration or observational/naturalistic studies using standardized measures of cardiovascular and subjective effects are available. The aim of this study was to evaluate the acute pharmacological effects of JWH-122 and JWH-210 recreational consumption in a 4 h observational study and assess their disposition in oral fluid (OF). Sixteen volunteers self-administered 1 mg dose of JWH-122 (n = 8) or 2.25 mg mean dose of JWH-210 (range 2-3 mg, n = 8) by inhalation (smoking). Physiological parameters including blood pressure (systolic and diastolic), heart rate (HR), and cutaneous temperature were measured. A set of visual analog scales, the 49-item short-form version of the Addiction Research Center Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) were used for the evaluation of subjective effects. OF was collected at baseline and at 10, 20, and 40 min and 1, 2, 3, and 4 h after self-administration. Statistically significant increases in systolic blood pressure (SBP), diastolic blood pressure (DBP), and HR were observed after JWH-122 self-administration but not after JWH-210 self-administration. JWH-210 self-administration produced significant changes in subjective drug effects, similar to those induced by THC (intensity, high, good effects, and hunger). The subjective effects following JWH-122 consumption were minimal. The maximal effects were mostly observed 20 min after intake. JWH-122 and JWH 210 OF concentration reached a peak 20 min after administration and could not be detected after 3 h. The results demonstrated a different pattern of effects of these two SCs. Due to the limitations of our observational study, further research with a larger sample and controlled studies are needed to better define the acute pharmacological effect and health risk profile of JWH-122 and JWH-210.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Comparison of Acute Pharmacological Effects of Methylone and MDMA Administration in Humans and Oral Fluid Concentrations as Biomarkers of Exposure

  • Poyatos, Lourdes|||0000-0002-4641-8600
  • Papaseit, Esther|||0000-0003-2620-4274
  • Olesti, Eulàlia|||0000-0001-8677-9964
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Ventura, Mireia|||0000-0003-1133-6872
  • Grifell, Marc|||0000-0001-9815-5761
  • Fonseca, Francina|||0000-0002-0779-6545
  • Torrens, Marta
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Carbón, Xoán|||0000-0003-1652-5488
Methylone is a synthetic cathinone that is usually used as a substitute for conventional psychostimulants, such as MDMA. Chemically, methylone is considered the β-keto analogue of MDMA, with which it presumably shares similar pharmacological effects. To date, the available data about the human pharmacology of methylone in humans are very scarce and are mainly derived from user experiences, published in internet forums or intoxication reports. Thus, an observational-naturalistic study was conducted to evaluate the acute pharmacological effects and determine biomarkers of exposure in oral fluid of methylone after oral self-administration in comparison to MDMA. Methylone induced the prototypical psychostimulant and empathogenic effects commonly associated with MDMA, although they were of lower intensity. Oral fluid concentrations of methylone can be considered a suitable biomarker of acute exposure, and oral fluid has been proven to be a useful biological matrix of detection. Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational-naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Markers of monocyte activation, inflammation, and microbial translocation are associated with liver fibrosis in alcohol use disorder

  • Fuster, Daniel|||0000-0003-1262-5860
  • García Calvo, Xavier|||0000-0001-8165-8717
  • Farré, Oriol
  • Zuluaga Blanco, Yenny Paola|||0000-0002-0247-0351
  • Bolao, Ferran|||0000-0002-9104-6615
  • Leis, Alba|||0000-0003-3928-7849
  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Rivas, Inmaculada|||0000-0003-2633-5530
  • Muga, Roberto|||0000-0001-6301-431X
Background: The association between markers of inflammation (interleukin (IL)-6 and IL-10), monocyte activation (sCD163 and sCD14), and microbial translocation (lipopolysaccharide (LPS) and LPS binding protein) and liver fibrosis in patients with alcohol use disorder (AUD) and no overt liver disease is not well established. Methods: We studied patients admitted for treatment of AUD at two hospitals in Barcelona. Advanced liver fibrosis (ALF) was defined as FIB-4.